IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 3,041.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,243 shares of the company’s stock after acquiring an additional 21,535 shares during the quarter. Russell Investments Group Ltd.’s holdings in IDEAYA Biosciences were worth $364,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Oppenheimer Asset Management Inc. grew its holdings in shares of IDEAYA Biosciences by 33.2% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company’s stock worth $189,000 after acquiring an additional 2,884 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of IDEAYA Biosciences by 9.6% in the 1st quarter. Rhumbline Advisers now owns 124,437 shares of the company’s stock worth $2,038,000 after acquiring an additional 10,876 shares during the last quarter. Palumbo Wealth Management LLC grew its holdings in shares of IDEAYA Biosciences by 65.8% in the 1st quarter. Palumbo Wealth Management LLC now owns 22,402 shares of the company’s stock worth $367,000 after acquiring an additional 8,893 shares during the last quarter. Swiss National Bank grew its holdings in shares of IDEAYA Biosciences by 0.8% in the 1st quarter. Swiss National Bank now owns 150,800 shares of the company’s stock worth $2,470,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of IDEAYA Biosciences by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock worth $83,417,000 after acquiring an additional 14,535 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IDYA. Royal Bank Of Canada raised IDEAYA Biosciences from an “outperform” rating to a “moderate buy” rating and decreased their target price for the stock from $57.00 to $30.00 in a research report on Wednesday, July 9th. TD Cowen began coverage on IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a “buy” rating for the company. JPMorgan Chase & Co. raised their target price on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an “overweight” rating in a research report on Monday, July 28th. The Goldman Sachs Group raised IDEAYA Biosciences to a “hold” rating and set a $25.00 target price for the company in a research report on Thursday, July 10th. Finally, Wells Fargo & Company began coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They issued an “overweight” rating and a $44.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $47.10.

IDEAYA Biosciences Trading Down 1.5%

IDYA opened at $24.55 on Tuesday. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -6.48 and a beta of 0.12. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $40.25. The stock has a fifty day moving average price of $23.33 and a 200 day moving average price of $20.49.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $3.48 million. The company’s revenue was up NaN% on a year-over-year basis. During the same period last year, the firm posted ($0.68) earnings per share. As a group, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.